Premium
Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Author(s) -
Gisondi P.,
Virga C.,
Piaserico S.,
Meneguzzo A.,
Odorici G.,
Conti A.,
Girolomoni G.
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19013
Subject(s) - biosimilar , infliximab , medicine , plaque psoriasis , psoriasis , dermatology , tumor necrosis factor alpha